^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HBM7008

    i
    Other names: HBM7008, HBM 7008, CLN-418, CLN418, CLN 418, HBM-7008
    Associations

    News

    Trials
    Company:
    Harbour BioMed
    Drug class:
    CD137 agonist, B7-H4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    CLN-418-001: CLN-418 Study on Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=48, Completed, Cullinan Therapeutics Inc. | Recruiting --> Completed | N=108 --> 48 | Trial completion date: Jun 2024 --> Sep 2024
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    HBM7008
    1year
    CLN-418, a clinical-stage B7H4 x 4–1BB bispecific antibody with potential to treat patients with a wide range of solid tumors (SITC 2023)
    Conclusions B7H4 and 4–1BB expression in cancer cells, PBMC and solid tumors, together with robust B7H4-dependent single agent activity of CLN-418 in preclinical tumor models, support the development of CLN-418 in patients with difficult-to-treat solid cancers. A Phase 1 dose-escalation trial of CLN-418 is ongoing (NCT05306444).
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    PD-L1 expression • VTCN1 underexpression
    |
    HBM7008
    over1year
    CLN-418 Study on Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, Cullinan Oncology, LLC | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HBM7008
    2years
    HBM7008 (B7H4x4-1BB HBICE) Synergizes HBM7004 (B7H4xCD3 HBICE) for Solid Tumor Therapy (SITC 2022)
    Ethics Approval The cancer tissue microarray was purchased from Fanpu Biotech, Inc. The company ensured ethical approval from the patients, and patient consent for publication.
    IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    HBM7004 • HBM7008